Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-PET: Doxorubicin & Docetaxel Neoadjuvant Chemotherapy in Breast Cancer
NCT01396655Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2006
- Primary completion
- Sep 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and pegylated liposomal doxorubicin in breast cancer, sponsored by Seoul National University Hospital. Primary endpoint: Pathologic Complete Response at 9 weeks. Started Jul 2006; status: completed.
02
Drugs
docetaxelpegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01396655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396655.